Group 1 - The core index of the Shenzhen-Hong Kong Stock Connect Medical Index (HKD) closed at 4355.33 points, down 0.53%, with a trading volume of 10.417 billion HKD and a turnover rate of 0.96% [1] - Among the constituent stocks, 8 stocks increased, with Aidi Te leading with a 3.21% rise, while 48 stocks decreased, with Baize Medical leading the decline at 6.52% [1] - The net outflow of main funds from the constituent stocks totaled 390 million HKD, while retail investors saw a net inflow of 497 million HKD [2] Group 2 - The Shenzhen-Hong Kong Stock Connect Medical Index has made adjustments in the last 10 days, incorporating 2 new stocks [2]

董事会进一步宣布，姜铮博士已辞任本公司助理总裁，自2025年12月29日起生效，由于彼希望投入更多 时间于家庭事务。 佰泽医疗(02609)发布公告，吕超先生(吕先生)自2025年12月29日起获委任为本公司总裁。 ...

董事会进一步宣布，姜铮博士已辞任本公司助理总裁，自2025年12月29日起生效，由于彼希望投入更多 时间于家庭事务。 智通财经APP讯，佰泽医疗(02609)发布公告，吕超先生(吕先生)自2025年12月29日起获委任为本公司总 裁。 ...

(1) 委 任 總 裁 (2) 助理總裁辭任 委任總裁 佰 澤 醫 療 集 團（「本公司」，連 同 其 附 屬 公 司 統 稱「本集團」）董 事（「董 事」）會 （「董事會」）欣 然 宣 佈，呂 超 先 生（「呂先生」）自2025年12月29日起獲委任為 本公司 總 裁。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內 容 概 不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示 概 不 就因本公告全部或任何部分內容而產生或因 依 賴該等內容而引致的任 何 損 失 承 擔 任 何 責 任。 Bayzed Health Group Inc 佰澤醫療集團 （根據開曼群島法律註冊成立的有限公司） （股份代號：2609） 呂 先 生 的 履 歷 詳 情 載 列 如 下： 呂 超 先 生，41歲，自2025年12月29日起獲委任為本公司 總 裁。呂 先 生 目 前 擔 任 本 公 司 助 理 總 裁 及 董 事 會 主 席 助 理，自2025年9月22日 起 履 職。 呂 先 生 在 企 業 戰 略 管 理、投 資 及 融 資 運 營、財 務 系 統 發 展 ...

Core Insights - The article highlights that Baize Medical (stock code: 02609.HK) has been awarded the "Annual Outstanding Healthcare Enterprise Award" and its CFO, Yao Le, received the "Annual Outstanding CFO Award," reflecting strong recognition from the capital market for the company's governance and professional team [1] - The healthcare industry is entering a phase of differentiation, shifting from scale expansion to value-driven growth, particularly in the oncology sector, which has become a national strategic focus due to rising cancer rates and an aging population [2] Industry Trends - The development path of private oncology medical institutions is being restructured, as the previous model of heavy asset investment and rapid expansion is becoming less viable. Over 70% of private oncology hospitals closed in 2025 faced structural shortcomings, such as "heavy equipment but light on talent" and "heavy marketing but light on service" [2] - The National Health Commission has issued guidelines to strengthen the specialized system for major diseases like cancer, encouraging private hospitals to focus on niche areas and participate in scientific research [2] - The private oncology medical market in China is projected to exceed 109.2 billion yuan by 2026, with a compound annual growth rate of 19.8% from 2022 to 2026, indicating strong growth potential [2] Company Strategy - Baize Medical is establishing differentiated competitive advantages through a systematic strategic layout, focusing on three core areas: academic leadership, regional deepening, and full-cycle service [3][4][6] - The company emphasizes "academic-led" development, integrating high-quality medical resources to create a sustainable clinical and research system, exemplified by the publication of the "Oncology Rehabilitation Expert Consensus (2025)" [3] - Baize Medical's strategy includes focusing on core regions and enhancing service capabilities through acquisitions, as demonstrated by the successful upgrade of a hospital in Henan, which increased its gross margin from 6.6% in 2022 to 18.6% in 2024 [4] - The company has built a comprehensive cancer health management system covering prevention, screening, diagnosis, treatment, and rehabilitation, enhancing service continuity and patient engagement [6] - Digital transformation initiatives, such as the implementation of a mobile payment system, have improved patient experience by reducing average waiting times by 30% [6] Conclusion - The recognition received by Baize Medical underscores its commitment to a patient-centered development philosophy and its comprehensive strengths in policy alignment, academic construction, and operational management [7] - The ongoing structural transformation in China's private healthcare sector necessitates a focus on medical essence, specialized capabilities, and service quality for companies to thrive in the new competitive landscape [7]

智通财经APP获悉，佰泽医疗(02609)今早盘初一度挫逾4%，低见4.11港元创历史新低，并跌穿招股价 4.22港元。截至发稿，跌2.56%，报4.19港元，成交额1073.2万港元。 消息面上，12月24日，佰泽医疗迎来基石解禁。据公司此前发布公告显示，其基石投资者Harvest Oriental SP须遵守禁售承诺最后日期为2025年12月23日，解禁股数约3531.78万股。今年上半年，佰泽医 疗实现收入5.75亿元(人民币，下同)，同比增加约0.7%；经调整净利润940万元，同比增长约72.8%。 ...

佰泽医疗(02609)今早盘初一度挫逾4%，低见4.11港元创历史新低，并跌穿招股价4.22港元。截至发稿， 跌2.56%，报4.19港元，成交额1073.2万港元。 消息面上，12月24日，佰泽医疗迎来基石解禁。据公司此前发布公告显示，其基石投资者Harvest Oriental SP须遵守禁售承诺最后日期为2025年12月23日，解禁股数约3531.78万股。今年上半年，佰泽医 疗实现收入5.75亿元(人民币，下同)，同比增加约0.7%；经调整净利润940万元，同比增长约72.8%。 ...

Group 1 - The core index of the Shenzhen-Hong Kong Stock Connect Medical Index (HKD) closed at 4370.16 points, down 0.94%, with a trading volume of 10.39 billion HKD and a turnover rate of 1.31% [1] - Among the constituent stocks, 11 stocks rose, with Furuimei Medical leading with a 2.4% increase, while 48 stocks fell, with Baize Medical leading the decline at 6.11% [1] - The net outflow of main funds from the constituent stocks amounted to 646 million HKD, while retail funds saw a net inflow of 606 million HKD [2] Group 2 - The Shenzhen-Hong Kong Stock Connect Medical Index has made adjustments in the last 10 days, adding 2 new stocks to its constituents [2]

Group 1 - The core index of the Shenzhen-Hong Kong Stock Connect Medical Index (983035) closed at 4439.36 points, down 1.05%, with a trading volume of 9.39 billion yuan and a turnover rate of 1.31% [1] - Among the constituent stocks, 11 stocks rose, with Furui Medical leading with a 2.4% increase, while 48 stocks fell, with Baize Medical leading the decline at 6.11% [1] - The net outflow of main funds from the Shenzhen-Hong Kong Stock Connect Medical Index constituents totaled 646 million yuan, while retail investors saw a net inflow of 606 million yuan [2] Group 2 - The Shenzhen-Hong Kong Stock Connect Medical Index made adjustments in the last 10 days, adding 2 new stocks to its constituents [2]

智通财经APP获悉，佰泽医疗(02609)盘中跌超6%，当前股价较9月高点已跌超50%。截至发稿，跌 5.24%，报4.34港元，成交额2529.52万港元。 消息面上，佰泽医疗基石投资者禁售期即将届满。据公司此前发布公告显示，其基石投资者Harvest Oriental SP须遵守禁售承诺最后日期为2025年12月23日，解禁股数约3531.78万股。今年上半年，佰泽医 疗实现收入5.75亿元(人民币，下同)，同比增加约0.7%；经调整净利润940万元，同比增长约72.8%。 ...